Urologix develops, manufactures and markets minimally-invasive medical products for the treatment of urological disorders. The company has developed non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia (BPH). Its less-invasive technology has been used on more than 225,000 patients, establishing Urologix as a clear leader in BPH treatment.